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The objective of this study was to investigate the in vivo activity of the lantibiotic lacticin 3147 against the luminescent
Staphylococcus aureus strain Xen 29 using a murine model. Female BALB/c mice (7 weeks old, 17g) were divided into groups
(n = 5) and infected with the Xen 29 strain via the intraperitoneal route at a dose of 1 × 106 cfu/animal. After 1.5hr, the animals
weretreatedsubcutaneouslywithdosesofphosphate-buﬀeredsaline(PBS;negativecontrol)orlacticin3147.Luminescentimaging
wascarried3and5hourspostinfection.Micewerethensacriﬁced,andthelevelsofS.aureusXen29intheliver,spleen,andkidneys
were quantiﬁed. Notably, photoluminescence and culture-based analysis both revealed that lacticin 3147 successfully controlled
the systemic spread of S. aureus in mice thus indicating that lacticin 3147 has potential as a chemotherapeutic agent for in vivo
applications.
1.Introduction
Staphylococcus aureus is one of the most signiﬁcant bacterial
pathogens and can cause diseases ranging from minor and
surgical site infections [1] to potentially life-threatening
endocarditis [2–4] and bacteraemia [5–8]. It is a particular
problem in hospitals as a consequence of the emergence
and dissemination of multidrug-resistant forms such as
methicillin-resistant S. aureus (MRSA), vancomycin inter-
mediate susceptibility S. aureus (VISA), and heterogenous
VISA (hVISA). The prevalence of these antibiotic resistant
forms means that the discovery of novel chemotherapeutic
agents to combat these pathogens is of key importance
[9, 10]. The lantibiotics (lanthionine-containing antibiotics
[11]) are a group of posttranslationally modiﬁed antimicro-
bial peptides of which nisin and lacticin 3147 are among the
most extensively investigated. A number of lantibiotics have
been noted to exhibit potent antimicrobial activity against
staphylococci of clinical relevance. In agar diﬀusion assays,
the type I lantibiotics epidermin, Pep5, epicidin K7, and
epilancin 280 display impressive levels of activity against
coagulase negative staphylococci (CNS) [12], and it has
been suggested that their potential could be exploited to
prevent the colonization of medical devices [12]. Nisin has
also been shown on several occasions to possess signiﬁcant
anti-Staphylococcus activity. When tested against 20 MRSA
strains, one study revealed that the minimum inhibitory
concentration (MIC) of nisin A ranged between 1.5 and
16mg/L [13], while a more recent investigation revealed
MICs of 0.5–4.1mg/L [14]. The in vitro activity of other
forms of nisin (nisin F, Q, and Z) against MRSA has also
recently been highlighted [15]. The in vivo activity of a
number of lantibiotics against staphylococci has also been
investigated. The eﬀectiveness of the epidermin-like mutacin
B-Ny266 was tested on mice infected by intraperitoneal (IP)
injectionwith3.1×107 cfuofS.aureusSmith/mouse.Imme-
diately after injection, mutacin B-Ny266 was administered,
also via the IP route, at concentrations of 1–10mg/kg of
mouse and was found to be protective [16]. More recently,
it has been established that microbisporicin, in addition
to having potent in vitro activity (MIC ≤ 0.13μg/mL),
eﬀectively controls murine septicemia caused by S. aureus
in female CD-1 mice (23–25g). The mice were infected via
the IP route with 1 × 106 cfu of S. aureus Smith 819 ATCC2 International Journal of Microbiology
19636 in 0.5 mls gastric hog mucin. Microbisporicin was
then administered intravenously or subcutaneously (SC) 10–
15mins after infection at ﬁnal concentrations of 10–15mg/L
[17]. The eﬀective dose 50 (ED50) of microbisporicin
was found to be 2.1mg/kg regardless of whether it was
administered via IV or SC. ED50 values were determined
on the bases of survival of the mice to the seventh day.
Higher doses of microbisporicin (≥200mg/kg) led to the
survival of all animals treated and were nontoxic [16]. Nisin
Fe ﬀectively controlled the MRSA strain, S. aureus K, in
immunocompromised Wistar rats following the introduc-
tion of 4 × 105 S. aureus cells into the nostrils of the rats
for 4 consecutive days before treating with 8192 arbitrary
units (AU) of nisin F intranasally for the subsequent 4 days
[18]. In contrast, however, when 1 x108 S. aureus Xen 36
cells were injected intraperitoneally, the administration of
a lower concentration of nisin F (640 AU) after 4 hours
succeeded in inhibiting the growth of the pathogen for only
15 minutes after which time the pathogen reemerged [19].
Finally, short- and long-term in vivo studies with mersacidin
established that this lantibiotic quite eﬀectively inhibited
MRSA introduced intranasally into immunocompromised
(hydrocortisone-treated) BALB/C mice [20]. For the short
term trial, the mice were infected on days 5, 7, and 9 with
3 × 102–104 cfu of the S. aureus strain. The mice were
then treated intranasally with mersacidin (1.66mg/kg per
treatment) twice a day on days 10, 11, and 12. For the longer
trial, the mice were challenged with S. aureus on days 5, 7, 9,
30, 32, and 34 and subsequently treated with mersacidin on
days 35, 36, and 37. In both cases the mersacidin treatment
successfully inhibited MRSA-induced rhinitis [20]. Notably,
acomparisonoftheinvitroandinvivoactivityofmersacidin
against a number of MRSA strains indicates that mersacidin
more eﬀectively inhibits S. aureus in vivo [21].
Lacticin 3147 is the most extensively investigated of
the two peptide lantibiotics. These peptides are active
as a consequence of the synergistic activity of two
lanthionine-containing peptides [22, 23]. Lacticin 3147 has
been found to exhibit potent in vitro activity against a
range of pathogenic bacteria including Clostridium diﬃcile,
vancomycin-resistant enterococci, Propionibacterium acne,
penicillin-resistant Pneumococcus, and Streptococcus mutans
[14, 24–26] as well as pathogenic mycobacteria such as
Mycobacterium avium subsp paratuberculosis and Mycobac-
terium tuberculosis H37Ra [27]. Of greatest relevance to
this study is the fact that lacticin 3147 possesses anti-
Staphylococcus activity. The lantibiotic itself, when incorpo-
rated into a teat seal, protects against S. aureus-associated
bovine mastitis [28, 29], while use of a lacticin 3147-
producing Lactococcus lactis DPC 3251 within a teat dip
inhibits S. aureus both in vitro and also in vivo [30]. The in
vitro activity of lacticin 3147 against clinical MRSA isolates
has also been established with MICs ranging from 1.9 to
15.4mg/L [14].
Despite lacticin 3147 being one of the most extensively
studied lantibiotics, its ability to control a systemic infection
caused by S. aureus, or indeed any other pathogen, has
not been investigated. Here we address this issue using
BALB/c mice infected via the IP route with S. aureus Xen
29, a strain of methicillin sensitive S. aureus (MSSA) that
has been genetically modiﬁed to express the Photorhabdus
luminescens lux genes to facilitate in vivo imaging. The ability
of subcutaneously administered lacticin 3147 to control
infectionwasassessedbyinvivoimagingandmicrobiological
analysis of the organs of sacriﬁced animals.
2.MaterialsandMethods
2.1. Antimicrobial Activity Assays. The in vitro activity of
lacticin 3147 and vancomycin (employed as a positive
control) against S. aureus Xen 29 was assessed through MIC
determination assays carried out in triplicate as described
previously [14] with puriﬁed lacticin 3147, prepared via
HPLC, again as described previously [14]. Vancomycin was
obtained from Sigma Aldrich.
2.2. Inoculum Preparation. S. aureus Xen 29 (derived from
the parental pleural isolate S. aureus 12600; Xenogen Cor-
poration, Almeda, CA) possesses a copy of the modiﬁed
luxABCDE operon of P. luminescens integrated at a single site
onthechromosome.S.aureusXen29wasculturedovernight
in brain heart infusion (BHI) broth aerobically at 37◦C
from an isolated colony growing on BHI agar containing
200μg/mL kanamycin. On the day of the trial, the overnight
culture was subcultured (1:100 dilution) into fresh BHI and
growntologphase(OD600nm of0.5).Thisculturewasdiluted
to facilitate the ultimate administration of the culture in the
form of a 1 × 106 cfu/100μLd o s ei n0 . 5 %h o gg a s t r i cm u c i n
(Sigma Aldrich).
2.3. Mouse Peritonitis Model. Mice were fed a standard
rodent diet ad libitum and all animal studies were approved
by the Animal Experimentation Ethics Committee. 13
BALB/c female mice (7 weeks old, 15g ±2g in weight) were
divided into 3 groups (A, B, C; n = 3, 5, and 5, resp.). At T0
mice in groups A–C received the 1 × 106 cfu dose (100μL
volume) via the IP route in 0.5% gastic hog mucin (Sigma
Aldrich). At T1.5hrs, the mice in group C were administered
lacticin 3147 (50.85mg/kg of Ltnα and 43.8mg/kg of Ltnβ,
corresponding to 30.76mM lacticin 3147/kg) in a single
dose and a second dose at T3hrs (25.425mg/kg Ltnα and
21.90mg/kgLtnβ;15.382mMlacticin3147/kg).Vancomycin
(50mg/kg; 33.6mM/kg) was administered at T1.5hrs and at
T3hrs to the mice in group B while the mice in group A
received PBS (once) as a control. Both antimicrobials and
PBS were adminisitered subcutaneously in 100μLd o s e s .
In vivo imaging was carried out at two time points that
is, 3 hours and 5 hours postinfection. Mice were anaes-
thetized for bioluminescent imaging via the inhalation of
aerosolized isoﬂurane mixed with oxygen. The mice were
then transferred to the IVIS chamber ventral side up, and
luminescence was measured over a 3-to-5mins exposure
time. The imaging system measures the number of photons
reaching each detector of the charged-couple device camera,
and the IVIS software translates these data into false color
images that display regions of intense luminescence with
red, moderate luminescence in yellow and green and mildInternational Journal of Microbiology 3
luminescence in blue. The images contained herein are
photographic images with an overlay of bioluminescence
that uses this computer-generated color scale [31]. The
mice were euthanized approximately 6 hours postinfection.
Liver, kidneys, and spleen were extracted. These organs were
mechanicallydisruptedandserialdilutionsmadewhichwere
subsequently plated in 100μLv o l u m e so nT S A−Kan200μg/mL
plates in order to enumerate the staphylococci present in
each organ.
2.4. Quantiﬁcation of Luminescence. Luminescent images
were quantiﬁed with IVIS imaging software. The total ﬂux
(number of photons/s/cm2) was calculated by a user deﬁned
area (region of interest) covering the infection site. The ﬂux
was averaged across all mice from each respective group. The
reduction in luminescence was quantiﬁed and represents a
comparison with the luminescence from mice administered
phosphate-buﬀered saline control at the same time point.
2.5. Statistical Analysis. The mean and standard error of the
mean (SEM) of the luminescence at the ﬁnal time point
and bacterial counts for the mice were calculated for all
groups. Diﬀerences in the bioluminescence and bacterial
counts analyzed through a one-way analysis of variance,
followed by the Holm-Sidak posttest (Sigma Stat, version
3.5).
3. Results/Discussion
3.1. Assessment of the In Vivo Activity of Lacticin 3147 against
S. aureus Xen 29 Using a Murine Peritonitis Model. The
ability of subcutaneously injected lacticin 3147 to control a
systemic S. aureus infection following the introduction of the
pathogen into the murine peritoneal cavity was investigated.
This involved in vivo imaging to detect levels of light emitted
by the pathogen within mice and through the postmortem
microbiological analysis of organs. Negative and positive
controls were employed in the form of mice treated with PBS
and the glycopeptide antibiotic vancomycin, respectively.
The target strain S. aureus Xen 29 is a methicillin sensitive
isolate which has been employed previously to facilitate an
investigation of acute in vivo infections [32–36]. Prior to
commencement of the study, the in vitro sensitivity of Xen
29 to lacticin 3147 was assessed. The corresponding MIC
values were 1.013mg/L and 19.1mg/L for vancomycin and
lacticin 3147, respectively (Table 1). For in vivo studies, mice
r e c e i v e dad o s eo f1× 106 cfu and, 1.5hrs postinfection,
were administered lacticin 3147 (50.85mg/kg of Ltnα and
43.8mg/kg of Ltnβ), vancomycin (50mg/kg), or PBS. At
T3hrs, the mice were subject to IVIS imaging, and second
doses of lacticin 3147 (25.425mg/kg and 21.90mg/kg) and
vancomycin (50mg/kg) were administered to the relevant
mice. IVIS analysis of the progression of the S. aureus Xen 29
infection showed that the pathogen spreads systemically and
eventually also occupies the thoracic cavity in mice injected
with PBS 5hrs (T5hrs) after injection of the pathogen. A sig-
niﬁcant (P = 0.000116) reduction in the RLU measurements
corresponding to the thoracic region of the lacticin 3147
Table 1: The standard deviation in all cases is 0 reﬂecting identical
triplicate results.
S. aureus Xen 29 MIC (mg/L)
Vancomycin 1.013
Lacticin 3147 19.1
treated group was evident when compared to that of the
PBS (negative) control group (Figure 1) at this time point
highlighting the ability of the lantibiotic to prevent systemic
spread of the S. aureus Xen 29 infection. In contrast, lacticin
3147doesnotsigniﬁcantlyreduceRLUvaluescorresponding
to the peritoneal cavity relative to the control. It may be
that lacticin 3147 is deﬁcient in penetrating the peritoneal
cavity (Figure 1). To further ascertain lacticin 3147 eﬃcacy,
culture-based analysis of staphylococcal levels in the organs
was determined after the mice were sacriﬁced. This analysis
further highlighted the success of lacticin 3147 in controlling
systemic infection. Lacticin 3147 treatment resulted in a
signiﬁcant reduction (P<0.05 in all cases; Figure 1)i n
pathogen numbers in the liver, spleen, and kidneys of the
mice treated relative to the PBS-treated controls (Figure 1).
As expected, vancomycin brought about a signiﬁcant
reduction in S. aureus levels relative to the PBS-treated con-
trols as determined by both bioimaging and culture-based
analysis. Notably, numbers of S. aureus in the spleens of
lacticin 3147- and vancomycin-treated mice were statistically
indiﬀerent. However, vancomycin treatment more success-
fully lowered S. aureus numbers in the liver and kidneys.
While both lacticin 3147 and vancomycin bind lipid II,
[10, 37, 38]d i ﬀerences exist with respect to their mechanism
of action. Vancomycin binds to the C-terminal D-Ala-D-
Ala motif of the pentapeptide of lipid II [10] whereas, on
the basis of similarities between Ltnα and mersacidin, it is
proposed that lacticin 3147 binds to the sugar phosphate
head group of lipid II [39]. Furthermore, lacticin 3147 is also
capable of forming pores in the membranes of target cells
[37, 38]. It should be noted that while similar mg/kg doses of
lacticin 3147 and vancomycin were employed in this study,
our in vitro investigations established that vancomycin is 19
times more potent than lacticin 3147 against Xen29 (MIC
values; 1.013mg/L and 19.1mg/L of vancomycin and lacticin
3147, resp.). Thus the dose of vancomycin administered
in vivo corresponded to 100-fold that of the in vitro MIC
whereas lacticin 3147 was administered at a level 8-fold
greater than its in vitro MIC. This may explain the enhanced
ability of vancomycin with respect to clearance of Xen 29
from the peritoneal cavity. This is the ﬁrst occasion upon
whichtheimpactoflacticin3147againstasystemicinfection
has been assessed and thus it is also the ﬁrst instance of
its administration subcutaneously. It may be that lacticin
3147 cannot travel to the peritoneum to eradicate the
infection but can prevent the spread of infection throughout
the blood stream. As stated previously, mersacidin has
successfullybeenshowntoinhibitasystemicMRSAinfection
in mice when administered via the subcutaneous route [20].
However, mersacidin is a one-component lantibiotic and is
also globular which may provide facile delivery through the4 International Journal of Microbiology
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Figure 1: Impact of lacticin 3147 on the systemic spread of S. aureus Xen 29 in mice. Images are of representative mice from each group 3
and 5 hours postinfection. Values (i.e., RLU measurements and cfu/mL of organs) represent averages of data collected at T5hrs,a n dP values
refer to the signiﬁcance of diﬀerences between the treated and untreated equivalents at T5hrs as determined by one-way analysis of variance,
followed by the Holm-Sidak posttest. The imaging system depicts false-color images representative of diﬀerent levels of total ﬂux. False color
imaging represents intense luminescence in red, moderate luminescence in green, and low level luminescence in blue/purple.
skin. It, like vancomycin, is quite a small peptide with a
molecular weight of 1, 825Da [40]. Lacticin 3147 consists
of 2 peptides with molecular weights of 3305Da (Ltnα)
and 2847Da (Ltnβ), and it may be that the larger size
of the individual peptides or a speciﬁc diﬃculty relating
the transport of one of the components to the peritoneal
cavity may be an issue. Mutacin B-Ny266 has also been
shown to protect against S. aureus in the peritoneum, but
this lantibiotic was administered intraperitoneally, and thus
transfer to the site of infection was not an issue [16].
3.2. Conclusion. I nc o n c l u s i o n ,h e r ew eh a v ep r o v i d e d
evidence that lacticin 3147 could be employed to treat
systemic infections. Both culture- and bioluminescence-
based analyses reveal that the lantibiotic signiﬁcantly reduces
numbers of the S. aureus Xen29 relative to the negative
control by preventing the dissemination of the pathogen.
Although these results are more promising than those
described when nisin F was employed in a similar manner
(19), diﬀerences with respect to the strains of S. aureus
employed, concentrations of lantibiotic, and other factors
mean that a direct comparison of outcomes is not possible.
Whilefurtherinvestigationsarerequired,overlongerperiods
of time, to more extensively assess the clinical potential
of lacticin 3147, it is worth noting that lacticin 3147
possesses many physicochemical properties that favour its
in vivo application. These include excellent activity over
a broad pH range, especially at physiological pH (pH 7),
the absence of cytotoxicity towards eukaryotic cells [41],
its broad spectrum of activity at nanomolar concentrations
[42], its alternative mode of action [38], and the presence
of (methyl)lanthionine bridges that confer structural rigidity
to lantibiotics and reduce proteolytic attack [43]. These
properties, accompanied by its ability to inhibit a systemic S.
aureus infection, make lacticin 3147 a promising candidate
for potential applications in human medicine.
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